United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics Corporation (Nasdaq: UTHR) reported a 6% year-over-year increase in total revenue for Q1 2021, reaching $379.1 million, compared to $356.3 million in Q1 2020. The company faced a significant net income decline of 79%, totaling $28.3 million, alongside a non-GAAP earnings increase of 2% to $162.1 million. Major revenue contributors included Tyvaso, which grew 20%, while Remodulin sales dipped by 10%. The report highlighted new product launches and ongoing clinical trials, including the TETON study, signaling positive growth prospects despite some challenges.

United Therapeutics Corporation (Nasdaq: UTHR) will report its first quarter 2021 financial results on May 5, 2021, before market opening. A teleconference is scheduled for the same day at 9:00 a.m. Eastern Time, accessible by phone and via webcast on the company's website. The company emphasizes its commitment to innovation and addressing the organ shortage crisis through its subsidiary, Lung Biotechnology. Forward-looking statements highlight potential risks and uncertainties that could impact future performance.

United Therapeutics Corporation (Nasdaq: UTHR) announced on April 19, 2021, the submission of a new drug application (NDA) to the FDA for its investigational product, Tyvaso DPI™, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The submission includes results from the BREEZE clinical study, which indicated safety and efficacy similar to existing treatments. If approved, Tyvaso DPI is expected to enhance patient convenience and potentially double the number of patients on Tyvaso therapy by the end of 2022.

United Therapeutics Corporation (Nasdaq: UTHR) has received FDA approval for Tyvaso (treprostinil) Inhalation Solution, now indicated for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). This marks Tyvaso's second FDA approval since its initial release for pulmonary arterial hypertension in 2009. With approximately 30,000 patients affected in the U.S., the approval is expected to significantly improve patient management. United Therapeutics aims to double the number of Tyvaso patients by the end of 2022, leveraging a 40% expansion in their field teams.

United Therapeutics Corporation (Nasdaq: UTHR) announced that Dr. Gil Golden, Executive Vice President and Chief Medical Officer, will present an overview of the company during a virtual session at the 10th Annual J.P. Morgan Napa Valley Forum on March 31, 2021. The presentation is scheduled from 12:00 p.m. to 12:45 p.m. EDT and will be accessible via a live webcast on the company's website. An archived version will be available for 30 days post-event. United Therapeutics focuses on innovative biotechnology and aims to address organ shortages through its subsidiary, Lung Biotechnology PBC.

United Therapeutics Corporation (Nasdaq: UTHR) will be presenting at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Dr. Martine Rothblatt, the company's CEO, will provide an overview of the business during a virtual fireside chat from 3:10 p.m. to 3:40 p.m. EDT. The session will be accessible via live webcast on their website, with an archived version available for 90 days post-event.

United Therapeutics is focused on innovative solutions for transplantable organs through its subsidiary, Lung Biotechnology PBC, aiming to address national organ shortages.

United Therapeutics Corporation (Nasdaq: UTHR) announced that Michael Benkowitz, President and COO, will present at the 41st Cowen Health Care Conference on March 3, 2021. Scheduled for 10:20 a.m. to 10:50 a.m. EST, the fireside chat will be accessible via live webcast on the company's website. An archived recording will be available after the session for 90 days. The company aims to enhance biotechnology value through innovation and quality, focusing on organ transplant technologies through its subsidiary, Lung Biotechnology PBC.

United Therapeutics Corporation (Nasdaq: UTHR) reported a 2% year-over-year increase in full-year net revenue, reaching $1.483 billion for 2020, attributed to record patient numbers on treprostinil-based therapies. The company anticipates four product launches in 2021, including the Remunity Pump and Tyvaso label expansion for PH-ILD, pending FDA approvals. Notably, net income for the year soared to $514.8 million from a loss of $104.5 million in 2019, indicating robust financial health and a strategic focus on innovation in pulmonary hypertension treatments.

United Therapeutics Corporation (Nasdaq: UTHR) is set to announce its fourth quarter and full year 2020 financial results on February 24, 2021, before market opening. A teleconference will be held the same day at 9:00 a.m. ET, accessible via phone and webcast. The company emphasizes its commitment to innovation and quality through its subsidiaries, such as Lung Biotechnology PBC, aimed at addressing organ shortages. The press release also includes a forward-looking statement disclaimer about potential risks and uncertainties.